Treatment patterns and outcomes among patients with metastatic melanoma treated in community practice.

Authors:
Mark S Walker
Mark S Walker
Washington University School of Medicine
United States
Carolina Reyes
Carolina Reyes
Memorial Sloan-Kettering Cancer Center
Sacha Satram-Hoang
Sacha Satram-Hoang
School of Medicine
United States
Edward J Stepanski
Edward J Stepanski
Rush University Medical Center
United States

Int J Dermatol 2014 Nov 6;53(11):e499-506. Epub 2014 Mar 6.

ACORN Research, LLC, Memphis, TN, USA.

Background: The primary systemic treatments for advanced melanoma have been chemotherapy and immunotherapy. New agents are currently in development.

Objectives: This study aimed to characterize treatment patterns and outcomes across several lines of therapy and to illustrate the treatment landscape prior to the approval of new therapies. The study endpoints were progression-free survival (PFS), overall survival (OS), and best overall response within line of therapy.

Methods: A retrospective chart analysis was conducted at 11 community oncology practices in the USA. Data for patients aged ≥18 years and diagnosed with stage IV and/or metastatic melanoma during 2006-2010 were analyzed. Primary endpoints were PFS within line of therapy and OS from the diagnosis of metastasis.

Results: Data on a total of 202 patients were collected. The sample was mostly male (60%) and Caucasian (88%), with a mean age of 61.3 years. Of the 202 patients, 56 (28%) never received any systemic therapy. In the remaining 146 patients, systemic therapies included temozolomide-based regimens (n = 68), platinum-based regimens without temozolomide (n = 16), other regimens (n = 23), and research regimens (n = 39). Of the 146 patients who received systemic therapy, not all did so immediately after the diagnosis of metastasis: 102 (51%) patients did so shortly after diagnosis and before first disease progression, and 44 (22%) did so after first disease progression. Response rates were very low (≤5%) and did not differ across treatment groups. Progressive disease was the most frequent best overall response category identified, with rates of 83, 78, and 89% in the first to third lines of treatment, respectively. In 146 patients receiving first-line systemic therapy, median PFS was 3.25 months. Median OS in the entire sample was 7.66 months.

Conclusions: Findings provided little evidence for any beneficial effects of the treatments available in the timeframe referred to in this study. Few patients (≤5%) responded to treatment, PFS among treated patients was short (3.25 months in first-line treatments, less in later lines), and there was no evidence of a differential effect of treatment regimens on PFS. There was no evidence of shorter survival in patients who never received systemic therapy. The high proportion of patients who did not receive any systemic therapy highlights the lack of effective therapies and underscores the unmet medical need in this patient population.

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.12427DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
November 2014
12 Reads

Publication Analysis

Top Keywords

systemic therapy
20
146 patients
12
received systemic
12
patients
12
therapy diagnosis
8
metastatic melanoma
8
disease progression
8
best response
8
patterns outcomes
8
treatment patterns
8
202 patients
8
patients received
8
therapy
7
systemic
7
treatment
7
regimens
5
pfs
5
shortly diagnosis
4
22% disease
4
progression response
4

References

(Supplied by CrossRef)

American Cancer Society et al.
2013
Cancer statistics, 2013
Siegel et al.
CA Cancer J Clin 2013
Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
Middleton et al.
J Clin Oncol 2000
Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview
Serrone et al.
J Exp Clin Cancer Res 2000
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993
Atkins et al.
J Clin Oncol 1999
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
Chapman et al.
J Clin Oncol 1999

Similar Publications